Europe
Some French employees of drug giant Sanofi will receive an unwanted Christmas present this year – pink slips. The company will lay off 670 employees in France on what has been reported as a “voluntary basis.”
The biotechnology company Iproteos, IBEC and the Vall d’Hebron Research Institute (VHIR) are set to develop an innovative treatment to slow down, stop and even reverse the growth of solid tumors, which represent more than 90% of cancer cases.
Study Will Evaluate Simultaneous Use of Radiofrequency and Cryo Surgical Ablation Devices in Cardiac Surgery Patients with Atrial Fibrillation
Facility to cement Park’s position in UK life sciences ecosystem
GlaxoSmithKline plc and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion).
Phase 2 study targeting a patient population with NASH-induced Stage 2 or 3 fibrosis
Medigene AG announced that researchers from Oslo University Hospital presented an update on clinical compassionate use (1) data of their dendritic cell (DC) vaccine utilizing Medigene’s DC vaccine technology for production.
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
In July 2017, Bayer launched a three-year, Phase III ASTEROID clinical trial of vilaprisan in patients with symptomatic uterine fibroids, with the intention of recruiting more than 3,600 patients in 900 sites in 40 countries.
Prior to being acquired by Medtronic, the two companies were involved in what the DOJ called kickback schemes to encourage unauthorized use of a medical device.
PRESS RELEASES